WEST PHARMACEUTICAL SERVICES INC
For the period ended Dec 31, 2025. Filed Feb 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC.
(Registrant)
By: /s/ Robert W. McMahon
Robert W. McMahon
Senior Vice President, Chief Financial Officer
February 17, 2026
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of West Pharmaceutical Services, Inc. and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Eric M. Green | President, Chief Executive Officer and Chair of the Board | February 17, 2026 |
| Eric M. Green | (Principal Executive Officer) | |
| /s/ Robert W. McMahon | Senior Vice President, Chief Financial Officer | February 17, 2026 |
| Robert W. McMahon | (Principal Financial Officer) | |
| /s/ Chad R. Winters | Vice President, Finance & Chief Accounting Officer | February 17, 2026 |
| Chad R. Winters | (Principal Accounting Officer) | |
| /s/ Mark A. Buthman | Director | February 17, 2026 |
| Mark A. Buthman | ||
| /s/ William F. Feehery, Ph.D. | Director | February 17, 2026 |
| William F. Feehery, Ph.D. | ||
| /s/ Robert F. Friel | Director | February 17, 2026 |
| Robert F. Friel | ||
| /s/ Janet B. Haugen | Director | February 17, 2026 |
| Janet B. Haugen | ||
| /s/ Thomas W. Hofmann | Director | February 17, 2026 |
| Thomas W. Hofmann | ||
| /s/ Molly E. Joseph | Director | February 17, 2026 |
| Molly E. Joseph | ||
| /s/ Deborah L.V. Keller | Director | February 17, 2026 |
| Deborah L.V. Keller | ||
| /s/ Myla P. Lai-Goldman, M.D. | Director | February 17, 2026 |
| Myla P. Lai-Goldman, M.D. | ||
| /s/ Stephen H. Lockhart, M.D., Ph.D. | Director | February 17, 2026 |
| Stephen H. Lockhart, M.D., Ph.D. | ||
| /s/ Douglas A. Michels | Director | February 17, 2026 |
| Douglas A. Michels | ||
| /s/ Paolo Pucci | Director | February 17, 2026 |
| Paolo Pucci | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.